title: Haemoglobinopathies in Greece: prevention programme over the past 35 years.
abstract: At present, prevention of thalassaemia and sickle cell disease is the only realistic approach to control the birth of new patients in countries having high numbers of carriers. This is fully justified because avoiding the birth of an ever increasing number of patients may allow a more effective use of the available resources in improving the management of the patients surviving today and alleviate the already overloaded public health system from the inevitable tremendous and ever increasing cost. Moreover, prenatal diagnosis may help couples at risk to have non-thalassaemic children. Greece is one of the countries where the mean frequency of carriers is approximately 7.5 per cent (population 11 million) and has set up a nationwide programme for carrier identification in the early seventies; this is provided through a dozen of specific Units attached to the major Blood Transfusion Services of the country, on a voluntary basis and free of charge. Spread of information through mass media, the schools, and other groups has greatly contributed in creating the necessary sensitization; obstetricians and antenatal Clinics are also instrumental to this effect. Prenatal diagnosis is offered centrally (Athens) and covers satisfactorily the estimated needs (500-600 annually); the total number has already exceeded 35,000. According to information obtained from the major paediatric hospitals all over the country, the number of thalassaemia major or SCD admitted for treatment over the last ten years has been around 15 yearly (instead of an estimate of 120-130).
authors.affiliation: University of Athens & Biomedical Research Foundation of the Academy of Athens, Athens, Greece.
authors.forename: Dimitris
authors.initials: D
authors.lastname: Loukopoulos
mesh_terms: D000755:Anemia, Sickle Cell / Q000175:diagnosis* / Q000453:epidemiology / Q000517:prevention & control*; D005260:Female; D006580:Genetic Carrier Screening; D006115:Greece / Q000453:epidemiology; D006801:Humans; D011247:Pregnancy; D011296:Prenatal Diagnosis / Q000379:methods; D011634:Public Health; D013789:Thalassemia / Q000175:diagnosis* / Q000453:epidemiology / Q000517:prevention & control*
references.citation: BMJ. 1997 Sep 27;315(7111):779-84
references.pmid: 9345170
references.citation: Bull World Health Organ. 1995;73(3):375-86
references.pmid: 7614670
references.citation: Gene Geogr. 1992 Apr-Aug;6(1-2):59-70
references.pmid: 1299316
references.citation: Clin Biochem. 2009 Dec;42(18):1757-66
references.pmid: 19591814
references.citation: Br Med J. 1980 Jun 7;280(6228):1347-50
references.pmid: 7388536
references.citation: Bull World Health Organ. 1982;60(5):643-60
references.pmid: 6983923
references.citation: Expert Rev Hematol. 2010 Feb;3(1):103-17
references.pmid: 21082937
references.citation: Semin Hematol. 1996 Jan;33(1):76-86
references.pmid: 8714587
references.citation: Ann N Y Acad Sci. 1985;445:357-75
references.pmid: 2409876
references.citation: Scand J Clin Lab Invest. 2007;67(1):39-69
references.pmid: 17365984
references.citation: Ann N Y Acad Sci. 1980;344:181-8
references.pmid: 6930867
references.citation: Br J Haematol. 1962 Jan;8:5-14
references.pmid: 14468797
references.citation: Am J Hum Genet. 1981 Jul;33(4):592-605
references.pmid: 7258188
references.citation: Eur J Hum Genet. 2010 Oct;18(10):1077-83
references.pmid: 20571509